Biopharma Competition Prospecting Safety 
PM360
DECEMBER 20, 2023
With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.
Clarivate
OCTOBER 7, 2021
What’s new from ESMO: Interim efficacy and safety analysis from the randomized KEYNOTE-716 study showed that the trial met its primary endpoint of RFS, with patients receiving Keytruda presenting an RFS of 90.5% This novel antibody-drug conjugate (ADC)ADC faces much competition, should it be approved. at 12-months compared to 83.1%
Expert insights. Personalized for you.
111 
Let's personalize your content